J. McCoy

509 total citations
19 papers, 421 citations indexed

About

J. McCoy is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, J. McCoy has authored 19 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in J. McCoy's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (4 papers) and Cancer Genomics and Diagnostics (4 papers). J. McCoy is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (4 papers) and Cancer Genomics and Diagnostics (4 papers). J. McCoy collaborates with scholars based in United States and Italy. J. McCoy's co-authors include David R. Gandara, Paul H. Gumerlock, Howard West, Marileila Varella‐Garcia, Wilbur A. Franklin, Fred R. Hirsch, Federico Cappuzzo, Rafał Dziadziuszko, Kari Chansky and Ana C. Xavier and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

J. McCoy

18 papers receiving 402 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. McCoy United States 9 350 312 100 74 24 19 421
Diana Gernhardt United States 7 200 0.6× 248 0.8× 135 1.4× 56 0.8× 22 0.9× 8 338
Luigi Cerbone Italy 10 222 0.6× 125 0.4× 109 1.1× 93 1.3× 24 1.0× 40 308
You Lu China 9 298 0.9× 251 0.8× 59 0.6× 46 0.6× 34 1.4× 22 338
J.C.-H. Yang Taiwan 5 281 0.8× 263 0.8× 94 0.9× 46 0.6× 18 0.8× 12 353
M.C. Garassino Italy 5 327 0.9× 267 0.9× 71 0.7× 90 1.2× 16 0.7× 13 367
H. Akamatsu Japan 4 279 0.8× 211 0.7× 68 0.7× 89 1.2× 19 0.8× 10 314
Pei Ni Ding Australia 5 311 0.9× 230 0.7× 124 1.2× 143 1.9× 13 0.5× 6 402
Susan E. Jorge Brazil 7 200 0.6× 137 0.4× 112 1.1× 51 0.7× 20 0.8× 22 303
Susan K. Roethke United States 5 234 0.7× 127 0.4× 121 1.2× 92 1.2× 26 1.1× 6 339
B.C. Cho South Korea 8 232 0.7× 204 0.7× 90 0.9× 47 0.6× 27 1.1× 33 280

Countries citing papers authored by J. McCoy

Since Specialization
Citations

This map shows the geographic impact of J. McCoy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. McCoy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. McCoy more than expected).

Fields of papers citing papers by J. McCoy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. McCoy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. McCoy. The network helps show where J. McCoy may publish in the future.

Co-authorship network of co-authors of J. McCoy

This figure shows the co-authorship network connecting the top 25 collaborators of J. McCoy. A scholar is included among the top collaborators of J. McCoy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. McCoy. J. McCoy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
McCoy, J., et al.. (2024). College Ruled: A Pathfinding Approach to Generative Storytelling. 1–10. 2 indexed citations
3.
4.
McCoy, J., et al.. (2023). Towards an Agency-centered Ontology of Game Mechanics. 1–4. 1 indexed citations
5.
McCoy, J., et al.. (2022). Never a Dull Moment: Believable Dynamic Character Beat Generation between Game World Events. Proceedings of the AAAI Conference on Artificial Intelligence and Interactive Digital Entertainment. 18(1). 279–281. 1 indexed citations
6.
Roy, Upal, Margaret M. Byrne, J. McCoy, Courtney Blair, & Jamie L. Studts. (2019). P2.11-32 Project ACTS (Adherence to CT Screening): Developing Patient Engagement Tools to Support Lung Cancer Screening Adherence. Journal of Thoracic Oncology. 14(10). S805–S806. 1 indexed citations
7.
Charu, Vivek, et al.. (2009). 9248 Safety of romiplostim for treatment of chemotherapy-induced thrombocytopenia (CIT) in patients with advanced non-small cell lung cancer (NSCLC). European Journal of Cancer Supplements. 7(2). 574–574. 11 indexed citations
8.
Hirsch, Fred R., Marileila Varella‐Garcia, Federico Cappuzzo, et al.. (2007). Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology. 18(4). 752–760. 231 indexed citations
9.
Gaspar, Laurie E., J. McCoy, Karen Kelly, et al.. (2006). 108. International Journal of Radiation Oncology*Biology*Physics. 66(3). S61–S62. 5 indexed citations
10.
Hirsch, F. R., Wilbur A. Franklin, J. McCoy, et al.. (2006). Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. Journal of Clinical Oncology. 24(18_suppl). 7072–7072. 19 indexed citations
11.
Kelly, Karen, Roy S. Herbst, John J. Crowley, et al.. (2006). Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A randomized phase II selectional trial SWOG 0342. Journal of Clinical Oncology. 24(18_suppl). 7015–7015. 20 indexed citations
12.
Davies, Angela M., J. McCoy, Primo N. Lara, et al.. (2006). Bortezomib + gemcitabine (Gem)/carboplatin (Carbo) results in encouraging survival in advanced non-small cell lung cancer (NSCLC): Results of a phase II Southwest Oncology Group (SWOG) trial (S0339). Journal of Clinical Oncology. 24(18_suppl). 7017–7017. 16 indexed citations
13.
Hirsch, W., J. McCoy, Federico Cappuzzo, et al.. (2005). O-107 FISH and Immunohistochemistry (IHC) can be used to selectNSCLC patients, who will not benefit from gefitinib treatment. Lung Cancer. 49. S38–S38. 9 indexed citations
14.
Gumerlock, Paul H., William Holland, W. Franklin, et al.. (2005). Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioalveolar carcinoma (BAC) patients (pts) treated with gefitinib. Journal of Clinical Oncology. 23(16_suppl). 7008–7008. 30 indexed citations
15.
Hirsch, F. R., David R. Gandara, J. McCoy, et al.. (2005). Increased EGFR gene copy number detected by fish is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126). Journal of Clinical Oncology. 23(16_suppl). 7030–7030. 17 indexed citations
16.
West, Howard, W. Franklin, Paul H. Gumerlock, et al.. (2004). Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Journal of Clinical Oncology. 22(14_suppl). 7014–7014. 8 indexed citations
17.
Akerley, Wallace, et al.. (2004). SWOG 0019: A phase II study of gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer (SCLC). Journal of Clinical Oncology. 22(14_suppl). 7202–7202. 2 indexed citations
18.
West, Howard, W. Franklin, Paul H. Gumerlock, et al.. (2004). Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Journal of Clinical Oncology. 22(14_suppl). 7014–7014. 43 indexed citations
19.
Akerley, Wallace, et al.. (2004). SWOG 0019: A phase II study of gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer (SCLC). Journal of Clinical Oncology. 22(14_suppl). 7202–7202. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Diana Gernhardt Breakdown of academic impact, for papers by Luigi Cerbone Breakdown of academic impact, for papers by You Lu Breakdown of academic impact, for papers by J.C.-H. Yang Breakdown of academic impact, for papers by M.C. Garassino Breakdown of academic impact, for papers by H. Akamatsu Breakdown of academic impact, for papers by Pei Ni Ding Breakdown of academic impact, for papers by Susan E. Jorge Breakdown of academic impact, for papers by Susan K. Roethke Breakdown of academic impact, for papers by B.C. Cho
Rankless by CCL
2026